143 related articles for article (PubMed ID: 36251015)
1. ATM- and ATR-induced primary ciliogenesis promotes cisplatin resistance in pancreatic ductal adenocarcinoma.
Chao YY; Huang BM; Peng IC; Lee PR; Lai YS; Chiu WT; Lin YS; Lin SC; Chang JH; Chen PS; Tsai SJ; Wang CY
J Cell Physiol; 2022 Dec; 237(12):4487-4503. PubMed ID: 36251015
[TBL] [Abstract][Full Text] [Related]
2. CD147 promotes DNA damage response and gemcitabine resistance via targeting ATM/ATR/p53 and affects prognosis in pancreatic cancer.
Zhou Y; Zheng M; Liu Z; Yang H; Zhu P; Jiang JL; Tang J; Chen ZN
Biochem Biophys Res Commun; 2020 Jul; 528(1):62-70. PubMed ID: 32456796
[TBL] [Abstract][Full Text] [Related]
3. Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer.
Gout J; Perkhofer L; Morawe M; Arnold F; Ihle M; Biber S; Lange S; Roger E; Kraus JM; Stifter K; Hahn SA; Zamperone A; Engleitner T; Müller M; Walter K; Rodriguez-Aznar E; Sainz B; Hermann PC; Hessmann E; Müller S; Azoitei N; Lechel A; Liebau S; Wagner M; Simeone DM; Kestler HA; Seufferlein T; Wiesmüller L; Rad R; Frappart PO; Kleger A
Gut; 2021 Apr; 70(4):743-760. PubMed ID: 32873698
[TBL] [Abstract][Full Text] [Related]
4. ATM Deficiency Generating Genomic Instability Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Therapy-Induced DNA Damage.
Perkhofer L; Schmitt A; Romero Carrasco MC; Ihle M; Hampp S; Ruess DA; Hessmann E; Russell R; Lechel A; Azoitei N; Lin Q; Liebau S; Hohwieler M; Bohnenberger H; Lesina M; Algül H; Gieldon L; Schröck E; Gaedcke J; Wagner M; Wiesmüller L; Sipos B; Seufferlein T; Reinhardt HC; Frappart PO; Kleger A
Cancer Res; 2017 Oct; 77(20):5576-5590. PubMed ID: 28790064
[TBL] [Abstract][Full Text] [Related]
5. OCIAD1 promoted pancreatic ductal adenocarcinoma migration by regulating ATM.
Ji W; Zheng K; Song B; Qin A; Chandoo A; Shao Z; Bi J; Yang X; Jin G; Shen X
Pancreatology; 2019 Jul; 19(5):751-759. PubMed ID: 31221523
[TBL] [Abstract][Full Text] [Related]
6. The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma.
Shi Q; Shen LY; Dong B; Fu H; Kang XZ; Yang YB; Dai L; Yan WP; Xiong HC; Liang Z; Chen KN
Cancer Lett; 2018 Sep; 432():56-68. PubMed ID: 29890208
[TBL] [Abstract][Full Text] [Related]
7. Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy.
Roger E; Gout J; Arnold F; Beutel AK; Müller M; Abaei A; Barth TFE; Rasche V; Seufferlein T; Perkhofer L; Kleger A
Cells; 2020 Sep; 9(9):. PubMed ID: 32948057
[TBL] [Abstract][Full Text] [Related]
8. ATM Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications.
Armstrong SA; Schultz CW; Azimi-Sadjadi A; Brody JR; Pishvaian MJ
Mol Cancer Ther; 2019 Nov; 18(11):1899-1908. PubMed ID: 31676541
[TBL] [Abstract][Full Text] [Related]
9. HDAC2 promotes loss of primary cilia in pancreatic ductal adenocarcinoma.
Kobayashi T; Nakazono K; Tokuda M; Mashima Y; Dynlacht BD; Itoh H
EMBO Rep; 2017 Feb; 18(2):334-343. PubMed ID: 28028031
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapeutic drugs-induced pyroptosis mediated by gasdermin E promotes the progression and chemoresistance of pancreatic cancer.
Li S; Yue M; Xu H; Zhang X; Mao T; Quan M; Ma J; Wang Y; Ge W; Wang Y; Xue S; Shentu D; Cui J; Wang L
Cancer Lett; 2023 Jun; 564():216206. PubMed ID: 37120007
[TBL] [Abstract][Full Text] [Related]
11.
Nanda N; Roberts NJ
Genes (Basel); 2020 Jan; 11(1):. PubMed ID: 31963441
[TBL] [Abstract][Full Text] [Related]
12. Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to Chemotherapy by Abrogating the TopBP1/ATR-Mediated DNA Damage Response.
Ding L; Madamsetty VS; Kiers S; Alekhina O; Ugolkov A; Dube J; Zhang Y; Zhang JS; Wang E; Dutta SK; Schmitt DM; Giles FJ; Kozikowski AP; Mazar AP; Mukhopadhyay D; Billadeau DD
Clin Cancer Res; 2019 Nov; 25(21):6452-6462. PubMed ID: 31533931
[TBL] [Abstract][Full Text] [Related]
13. Ciliogenesis and Hedgehog signalling are suppressed downstream of KRAS during acinar-ductal metaplasia in mouse.
Bangs FK; Miller P; O'Neill E
Dis Model Mech; 2020 Jul; 13(7):. PubMed ID: 32571902
[TBL] [Abstract][Full Text] [Related]
14. Pancreatic cancer and precursor pancreatic intraepithelial neoplasia lesions are devoid of primary cilia.
Seeley ES; Carrière C; Goetze T; Longnecker DS; Korc M
Cancer Res; 2009 Jan; 69(2):422-30. PubMed ID: 19147554
[TBL] [Abstract][Full Text] [Related]
15. Clinical Characteristics of Patients With Pancreatic Cancer and Pathogenic
Hannan Z; Yu S; Domchek S; Mamtani R; Reiss KA
JNCI Cancer Spectr; 2021 Apr; 5(2):. PubMed ID: 33733050
[TBL] [Abstract][Full Text] [Related]
16. Loss of the tumor suppressor BIN1 enables ATM Ser/Thr kinase activation by the nuclear protein E2F1 and renders cancer cells resistant to cisplatin.
Folk WP; Kumari A; Iwasaki T; Pyndiah S; Johnson JC; Cassimere EK; Abdulovic-Cui AL; Sakamuro D
J Biol Chem; 2019 Apr; 294(14):5700-5719. PubMed ID: 30733337
[TBL] [Abstract][Full Text] [Related]
17. Loss of ATM accelerates pancreatic cancer formation and epithelial-mesenchymal transition.
Russell R; Perkhofer L; Liebau S; Lin Q; Lechel A; Feld FM; Hessmann E; Gaedcke J; Güthle M; Zenke M; Hartmann D; von Figura G; Weissinger SE; Rudolph KL; Möller P; Lennerz JK; Seufferlein T; Wagner M; Kleger A
Nat Commun; 2015 Jul; 6():7677. PubMed ID: 26220524
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma.
Mikamori M; Yamada D; Eguchi H; Hasegawa S; Kishimoto T; Tomimaru Y; Asaoka T; Noda T; Wada H; Kawamoto K; Gotoh K; Takeda Y; Tanemura M; Mori M; Doki Y
Sci Rep; 2017 Feb; 7():42339. PubMed ID: 28198398
[TBL] [Abstract][Full Text] [Related]
19. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
[TBL] [Abstract][Full Text] [Related]
20. Role of primary cilium in pancreatic ductal adenocarcinoma (Review).
Sabanovic B; Giulietti M; Piva F
Int J Oncol; 2020 Nov; 57(5):1095-1102. PubMed ID: 33491761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
